Hackensack University Medical Center
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Mar 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,184,113 | Ex Vivo Human Multiple Myeloma Cancer Niche and Its Use as a Model for Personalized Treatment of Multiple Myeloma In force · Medium confidence | In force | Medium confidence | |
| US 9,506,118 | Fibroblast Growth FACTOR-2 (FGF2) and SYNDECAN-1 (SDC1) as Biomarkers for Poor Outcome Hodgkin Lymphoma Patients In force · High confidence | In force | High confidence | |
| US 10,195,466 | Method for treating skin cancer using radiation therapy In force · USPTO record | In force | USPTO record | |
| US 9,937,154 | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases In force · USPTO record | In force | USPTO record | |
| US 12,649,905 | Methods for Treating an Immune Disorder-Related Disease by Reducing Autoreactivity in a T Cell Compartment In force · High confidence | In force | High confidence | |
| US 11,066,648 | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans In force · USPTO record | In force | USPTO record | |
| US 10,729,730 | Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans In force · USPTO record | In force | USPTO record | |
| US 12,023,357 | Rejuvenated aged hematopoietic stem cells and methods of use In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 8: 1 patent in force now held by others · 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 3 no status recorded